仙壇股份(002746.SZ):控股股東一致行動人增持165.13萬股並擬繼續增持
格隆匯7月15日丨仙壇股份(002746.SZ)公佈,公司近日收到控股股東、董事長王壽純的一致行動人仙潤控股的通知,已於2021年7月15日通過集中競價方式買入公司股份165.1324萬股,佔公司總股本的0.19%,買入均價為6.5850元,買入金額約為1087.40萬元。
仙潤控股擬自該次公吿之日起6個月內通過深交所交易系統允許的方式,包括但不限於集中競價交易、大宗交易等方式繼續適時增持公司股份,擬增持的金額累計不低於人民幣2000萬元且不超過人民幣3000萬元(含該次已買入的股份金額1087.40萬元)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.